论文部分内容阅读
概述:受2015十月在北京举行的第一届中国抗抑郁药研究与发展峰会上的讨论的启发,我们撰写了这篇述评。该峰会由中国医师协会精神科医师分会精神药理学和药物治疗工作委员会(Chinese Psychiatrist Psychopharmacology Commission,CPPC)发起,参与人员包括一流的精神科临床医生、神经科学研究者和国内外大型制药企业研发人员,会议重点讨论了那些限制了更有效的抗抑郁药物发展的主要问题。在没有明确的抑郁症生物标志物的情况下,临床医生必须在临床现象的基础上做出治疗决策;缺乏明确的生物靶点导致目前可用的抗抑郁药需要很长一段时间才有效,完全缓解率低,并且复发率高。中国神经科学家对抑郁症的基础研究是国际公认的,但他们提出的。作为治疗抑郁症潜在的候选化学成分大部分在临床试验时失败了。这种试剂的高失败率和大部分可用药物的不令人满意的结果迅速增加了新药进入市场的成本,所以制药公司更喜欢“调整”目前的药物而不是冒资金风险来支持新的抗抑郁药的发展。因此,发展新的、更有效的抑郁症治疗成为一个僵局。鉴于抑郁症对中国和其他国家的经济发展的巨大影响,在临床医生、研究人员和制药行业的共同努力下积极争取政府和社区的支持来克服这种僵局是必不可少的。
Summary: Inspired by the discussions at the first China Antidepressant Research and Development Summit held in Beijing in October 2015, we wrote this review. The Summit was initiated by the Chinese Psychiatrist Psychopharmacology Commission (CPPC), a member of the Psychiatrist Association of the Chinese Medical Association. Participants include first-rate psychiatrists, neuroscientists and researchers at major pharmaceutical companies both at home and abroad , The conference focused on the main issues that limited the development of more effective antidepressants. Without a clear biomarker of depression, clinicians must make treatment decisions based on clinical findings; the lack of a clear bio-target has led to the long-lasting and complete remission of currently available antidepressants Low rate, and high recurrence rate. Chinese neuroscientists’ basic research on depression is internationally recognized, but they are proposed. Most of the potential candidate chemotherapeutics for the treatment of depression have failed in clinical trials. The high failure rate of this reagent and the unsatisfactory results of most of the available drugs quickly add to the cost of bringing new drugs to market, so pharmaceutical companies prefer to “tweak” current drugs instead of risking funding risks to support new Development of antidepressants. Therefore, the development of new and more effective treatment of depression has become an impasse. Given the tremendous impact of depression on the economic development of China and other countries, it is essential to work actively with government and community support to overcome this impasse with the concerted efforts of clinicians, researchers and the pharmaceutical industry.